Regulating Biopharming: The Prism of Farmer Knowledge

Farmers have local knowledge relevant to the prospective assessment of biopharming—the farming of transgenic plants and animals genetically modified to produce pharmaceutical substances for use in humans or animals. However, biopharming regulatory regimes are being constructed in ways that render farmers' knowledge irrelevant. The exclusion of farmer knowledge is traceable to what we call its politico-epistemic unworkability as regulatory knowledge in regulatory regimes characterised not only by a focus on risk but also by pre-commitments to market-driven innovation and individual freedom of choice. Such innovation requires predictability in the regulatory environment, which is supplied in part through regulatory authorities' adoption of risk-assessment methodologies that both assume predictability (of natural and social worlds) and generate predictable decision outcomes. These regulatory approaches are co-constituted with scientific knowledge of gene flow developed through studies that can demonstrate a reliable and readily modellable decline of undesirable effect across space or time and therefore make possible the setting of clear and workable parameters for risk management. The farmers' knowledge discussed here highlights the extent to which this is a process of co-production. Moreover, it suggests that the claimed economic advantages of outdoor biopharming, achieved through the substitution of agronomic practice for laboratory infrastructure, depend both on natural processes that always also threaten to undermine confinement and on the habitus of successful farmers, which may in fact be incompatible with the kind of risk management that biopharming requires.